Prenetics Partners with Giannis Antetokounmpo as IM8 Shareholder, Targets $200M 2026 Sales
Prenetics added NBA Champion Giannis Antetokounmpo as IM8 global partner and shareholder, becoming the first NBA athlete equity holder in a NASDAQ-listed health brand. Since its December 2024 launch, IM8 reached $100 million ARR in 11 months, delivered over 22 million servings and targets $180–200 million revenue in 2026.
1. Partnership with Giannis Antetokounmpo
Prenetics named Giannis Antetokounmpo as IM8 global partner and became the first NBA athlete shareholder in a NASDAQ-listed health and longevity brand under a multi-year agreement connecting the athlete’s 35 million followers with IM8’s premium supplement line.
2. IM8 Growth Metrics
Since its December 2024 launch, IM8 reached $100 million in annualized recurring revenue within 11 months, delivered over 22 million servings across 31 countries, logged 750,000 customer purchases, and forecasts $180–200 million in full-year 2026 revenue.
3. Strategic Implications and Outlook
The Giannis partnership is expected to expand IM8’s addressable market among 18–34 year-olds, leverage NBA broadcasts in 215 countries, reinforce cross-sport credibility with four athlete equity holders, and support Prenetics’s path to adjusted EBITDA profitability by Q4 2027 with $160 million liquidity and zero debt.